share_log

Biora Therapeutics Achieves Interim Results For Clinical Trial Of BT-600, Advancing NaviCap Platform Development

Benzinga ·  Apr 4 20:04

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon

All NaviCap devices performed as intended and were well tolerated, with no safety signals observed

Multiple-ascending dose (MAD) portion of the trial is underway and progressing well

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today shared additional positive interim results from the single-ascending dose (SAD) clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap device that delivers a proprietary liquid formulation of...

Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment